866-997-4948(US-Canada Toll Free)

Epithelial Ovarian Cancer - Pipeline Review, H2 2015

Published By :

Global Markets Direct

Published Date : Oct 2015

Category :

Ovarian Cancer

No. of Pages : 450 Pages

Epithelial Ovarian Cancer - Pipeline Review, H2 2015

Summary

Global Markets Directs, Epithelial Ovarian Cancer - Pipeline Review, H2 2015, provides an overview of the Epithelial Ovarian Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Epithelial Ovarian Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epithelial Ovarian Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Epithelial Ovarian Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Epithelial Ovarian Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Epithelial Ovarian Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Epithelial Ovarian Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Epithelial Ovarian Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Epithelial Ovarian Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Epithelial Ovarian Cancer Overview 11
Therapeutics Development 12
Pipeline Products for Epithelial Ovarian Cancer - Overview 12
Pipeline Products for Epithelial Ovarian Cancer - Comparative Analysis 13
Epithelial Ovarian Cancer - Therapeutics under Development by Companies 14
Epithelial Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes 20
Epithelial Ovarian Cancer - Pipeline Products Glance 21
Late Stage Products 21
Clinical Stage Products 22
Early Stage Products 23
Epithelial Ovarian Cancer - Products under Development by Companies 24
Epithelial Ovarian Cancer - Products under Investigation by Universities/Institutes 30
Epithelial Ovarian Cancer - Companies Involved in Therapeutics Development 31
AbbVie Inc. 31
Acceleron Pharma, Inc. 32
Adaptimmune Limited 33
Amgen Inc. 34
Ascenta Therapeutics, Inc. 35
Astex Pharmaceuticals, Inc. 36
AstraZeneca Plc 37
Bayer AG 38
Bionomics Limited 39
BioNumerik Pharmaceuticals, Inc. 40
Boehringer Ingelheim GmbH 41
Caladrius Biosciences, Inc. 42
Celldex Therapeutics, Inc. 43
Celon Pharma Sp. z o.o. 44
Celsion Corporation 45
Cerulean Pharma, Inc. 46
Clovis Oncology, Inc. 47
Dr. Reddy's Laboratories Limited 48
EirGenix Inc. 49
Eisai Co., Ltd. 50
Eli Lilly and Company 51
Epirus Biopharmaceuticals, Inc. 52
Exelixis, Inc. 53
F. Hoffmann-La Roche Ltd. 54
Genentech, Inc. 55
Genor BioPharma Co., Ltd. 56
Glycotope GmbH 57
Hetero Drugs Limited 58
ImmunoGen, Inc. 59
Immunotope, Inc. 60
Incyte Corporation 61
Innate Immunotherapeutics Limited 62
Johnson & Johnson 63
Mabion SA 64
MabVax Therapeutics Holdings, Inc. 65
MedImmune, LLC 66
Merck & Co., Inc. 67
Millennium Pharmaceuticals, Inc. 68
Mycenax Biotech Inc. 69
Novartis AG 70
Oasmia Pharmaceutical AB 71
OBI Pharma, Inc. 72
Oncobiologics, Inc. 73
Oncolytics Biotech Inc. 74
Otsuka Holdings Co., Ltd. 75
Oxford BioMedica Plc 76
OXiGENE, Inc. 77
Pfizer Inc. 78
Pharma Mar, S.A. 79
Pharmacyclics, Inc. 80
Prima BioMed Ltd. 81
PsiOxus Therapeutics Limited 82
Sanofi 83
Sanofi Pasteur SA 84
Shenzen SiBiono GeneTech Co., Ltd 85
Sotio a.s. 86
Synta Pharmaceuticals Corp. 87
Tesaro, Inc. 88
TetraLogic Pharmaceuticals 89
Tyrogenex, Inc. 90
VentiRx Pharmaceuticals, Inc. 91
Epithelial Ovarian Cancer - Therapeutics Assessment 92
Assessment by Monotherapy Products 92
Assessment by Target 93
Assessment by Mechanism of Action 98
Assessment by Route of Administration 103
Assessment by Molecule Type 105
Drug Profiles 107
abexinostat hydrochloride - Drug Profile 107
abiraterone acetate - Drug Profile 110
ABT-898 - Drug Profile 113
alisertib - Drug Profile 114
anetumab ravtansine - Drug Profile 118
Antisense Oligonucleotide for Ovarian and Colorectal Cancer - Drug Profile 120
AT-406 - Drug Profile 121
AZD-1775 - Drug Profile 124
bevacizumab - Drug Profile 126
bevacizumab biosimilar - Drug Profile 132
bevacizumab biosimilar - Drug Profile 133
bevacizumab biosimilar - Drug Profile 134
bevacizumab biosimilar - Drug Profile 135
bevacizumab biosimilar - Drug Profile 136
bevacizumab biosimilar - Drug Profile 137
bevacizumab biosimilar - Drug Profile 138
bevacizumab biosimilar - Drug Profile 139
bevacizumab biosimilar - Drug Profile 140
birinapant - Drug Profile 141
BNC-105 - Drug Profile 144
cabozantinib s-malate - Drug Profile 146
CDX-1401 - Drug Profile 150
Cell Therapy to Target NY-ESO-1 for Oncology - Drug Profile 152
cositecan - Drug Profile 154
CRLX-101 - Drug Profile 156
CVac - Drug Profile 159
dalantercept - Drug Profile 162
DCVAC/OvCa - Drug Profile 164
DMUC-4064A - Drug Profile 165
E-7046 - Drug Profile 166
elesclomol - Drug Profile 167
eltrapuldencel-T - Drug Profile 169
enadenotucirev - Drug Profile 172
epacadostat - Drug Profile 174
erismodegib - Drug Profile 176
fosbretabulin tromethamine - Drug Profile 179
ganetespib - Drug Profile 183
GEN-1 - Drug Profile 187
Gene Therapy to Activate p53 for Oncology - Drug Profile 190
guadecitabine - Drug Profile 191
IMT-1012 - Drug Profile 195
LCL-161 - Drug Profile 196
lifastuzumab vedotin - Drug Profile 198
lurbinectedin - Drug Profile 200
MesoCART - Drug Profile 203
mirvetuximab soravtansine - Drug Profile 204
MIS-416 - Drug Profile 206
motolimod - Drug Profile 209
MV-NIS - Drug Profile 211
NERX-313E - Drug Profile 213
NERX-505X - Drug Profile 214
nintedanib - Drug Profile 216
niraparib - Drug Profile 221
NSC-748933 - Drug Profile 223
OBI-822/821 - Drug Profile 224
olaratumab - Drug Profile 226
Oncolytic Virus to Target Carcinoembryonic Antigen for Oncology - Drug Profile 228
OPB-111001 - Drug Profile 230
paclitaxel - Drug Profile 231
PankoMab-GEX - Drug Profile 233
pelareorep - Drug Profile 234
pembrolizumab - Drug Profile 239
PF-06647263 - Drug Profile 248
prexasertib - Drug Profile 249
Procure - Drug Profile 251
Protein to Antagonize Frizzled Receptors for Epithelial Ovarian Cancer - Drug Profile 252
ralimetinib mesylate - Drug Profile 253
regorafenib - Drug Profile 254
rucaparib phosphate - Drug Profile 258
SAR-408701 - Drug Profile 261
SC-003 - Drug Profile 262
Stem Cell Therapy to Activate Interferon Beta for Epithelial Ovarian Cancer - Drug Profile 263
trabectedin - Drug Profile 264
trebananib - Drug Profile 269
tremelimumab - Drug Profile 272
TroVax - Drug Profile 275
Vaccine for Oncology - Drug Profile 278
Vaccine to Target Cellular Tumor Antigen p53 for Oncology - Drug Profile 279
Vaccine to Target IGFBP-2 for Epithelial Ovarian Cancer - Drug Profile 280
varlilumab - Drug Profile 281
VCP-2292 - Drug Profile 283
veliparib - Drug Profile 284
X-82 - Drug Profile 288
Epithelial Ovarian Cancer - Recent Pipeline Updates 290
Epithelial Ovarian Cancer - Dormant Projects 434
Epithelial Ovarian Cancer - Discontinued Products 437
Epithelial Ovarian Cancer - Product Development Milestones 438
Featured News & Press Releases 438
Appendix 443
Methodology 443
Coverage 443
Secondary Research 443
Primary Research 443
Expert Panel Validation 443
Contact Us 443
Disclaimer 444

List of Tables
Number of Products under Development for Epithelial Ovarian Cancer, H2 2015 18
Number of Products under Development for Epithelial Ovarian Cancer - Comparative Analysis, H2 2015 19
Number of Products under Development by Companies, H2 2015 21
Number of Products under Development by Companies, H2 2015 (Contd..1) 22
Number of Products under Development by Companies, H2 2015 (Contd..2) 23
Number of Products under Development by Companies, H2 2015 (Contd..3) 24
Number of Products under Development by Companies, H2 2015 (Contd..4) 25
Number of Products under Investigation by Universities/Institutes, H2 2015 26
Comparative Analysis by Late Stage Development, H2 2015 27
Comparative Analysis by Clinical Stage Development, H2 2015 28
Comparative Analysis by Early Stage Development, H2 2015 29
Products under Development by Companies, H2 2015 30
Products under Development by Companies, H2 2015 (Contd..1) 31
Products under Development by Companies, H2 2015 (Contd..2) 32
Products under Development by Companies, H2 2015 (Contd..3) 33
Products under Development by Companies, H2 2015 (Contd..4) 34
Products under Development by Companies, H2 2015 (Contd..5) 35
Products under Investigation by Universities/Institutes, H2 2015 36
Epithelial Ovarian Cancer - Pipeline by AbbVie Inc., H2 2015 37
Epithelial Ovarian Cancer - Pipeline by Acceleron Pharma, Inc., H2 2015 38
Epithelial Ovarian Cancer - Pipeline by Adaptimmune Limited, H2 2015 39
Epithelial Ovarian Cancer - Pipeline by Amgen Inc., H2 2015 40
Epithelial Ovarian Cancer - Pipeline by Ascenta Therapeutics, Inc., H2 2015 41
Epithelial Ovarian Cancer - Pipeline by Astex Pharmaceuticals, Inc., H2 2015 42
Epithelial Ovarian Cancer - Pipeline by AstraZeneca Plc, H2 2015 43
Epithelial Ovarian Cancer - Pipeline by Bayer AG, H2 2015 44
Epithelial Ovarian Cancer - Pipeline by Bionomics Limited, H2 2015 45
Epithelial Ovarian Cancer - Pipeline by BioNumerik Pharmaceuticals, Inc., H2 2015 46
Epithelial Ovarian Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2015 47
Epithelial Ovarian Cancer - Pipeline by Caladrius Biosciences, Inc. , H2 2015 48
Epithelial Ovarian Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2015 49
Epithelial Ovarian Cancer - Pipeline by Celon Pharma Sp. z o.o., H2 2015 50
Epithelial Ovarian Cancer - Pipeline by Celsion Corporation, H2 2015 51
Epithelial Ovarian Cancer - Pipeline by Cerulean Pharma, Inc., H2 2015 52
Epithelial Ovarian Cancer - Pipeline by Clovis Oncology, Inc., H2 2015 53
Epithelial Ovarian Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H2 2015 54
Epithelial Ovarian Cancer - Pipeline by EirGenix Inc., H2 2015 55
Epithelial Ovarian Cancer - Pipeline by Eisai Co., Ltd., H2 2015 56
Epithelial Ovarian Cancer - Pipeline by Eli Lilly and Company, H2 2015 57
Epithelial Ovarian Cancer - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2015 58
Epithelial Ovarian Cancer - Pipeline by Exelixis, Inc., H2 2015 59
Epithelial Ovarian Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 60
Epithelial Ovarian Cancer - Pipeline by Genentech, Inc., H2 2015 61
Epithelial Ovarian Cancer - Pipeline by Genor BioPharma Co., Ltd., H2 2015 62
Epithelial Ovarian Cancer - Pipeline by Glycotope GmbH, H2 2015 63
Epithelial Ovarian Cancer - Pipeline by Hetero Drugs Limited, H2 2015 64
Epithelial Ovarian Cancer - Pipeline by ImmunoGen, Inc., H2 2015 65
Epithelial Ovarian Cancer - Pipeline by Immunotope, Inc., H2 2015 66
Epithelial Ovarian Cancer - Pipeline by Incyte Corporation, H2 2015 67
Epithelial Ovarian Cancer - Pipeline by Innate Immunotherapeutics Limited, H2 2015 68
Epithelial Ovarian Cancer - Pipeline by Johnson & Johnson, H2 2015 69
Epithelial Ovarian Cancer - Pipeline by Mabion SA, H2 2015 70
Epithelial Ovarian Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H2 2015 71
Epithelial Ovarian Cancer - Pipeline by MedImmune, LLC, H2 2015 72
Epithelial Ovarian Cancer - Pipeline by Merck & Co., Inc., H2 2015 73
Epithelial Ovarian Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 74
Epithelial Ovarian Cancer - Pipeline by Mycenax Biotech Inc., H2 2015 75
Epithelial Ovarian Cancer - Pipeline by Novartis AG, H2 2015 76
Epithelial Ovarian Cancer - Pipeline by Oasmia Pharmaceutical AB, H2 2015 77
Epithelial Ovarian Cancer - Pipeline by OBI Pharma, Inc., H2 2015 78
Epithelial Ovarian Cancer - Pipeline by Oncobiologics, Inc., H2 2015 79
Epithelial Ovarian Cancer - Pipeline by Oncolytics Biotech Inc., H2 2015 80
Epithelial Ovarian Cancer - Pipeline by Otsuka Holdings Co., Ltd., H2 2015 81
Epithelial Ovarian Cancer - Pipeline by Oxford BioMedica Plc, H2 2015 82
Epithelial Ovarian Cancer - Pipeline by OXiGENE, Inc., H2 2015 83
Epithelial Ovarian Cancer - Pipeline by Pfizer Inc., H2 2015 84
Epithelial Ovarian Cancer - Pipeline by Pharma Mar, S.A., H2 2015 85
Epithelial Ovarian Cancer - Pipeline by Pharmacyclics, Inc., H2 2015 86
Epithelial Ovarian Cancer - Pipeline by Prima BioMed Ltd., H2 2015 87
Epithelial Ovarian Cancer - Pipeline by PsiOxus Therapeutics Limited, H2 2015 88
Epithelial Ovarian Cancer - Pipeline by Sanofi, H2 2015 89
Epithelial Ovarian Cancer - Pipeline by Sanofi Pasteur SA, H2 2015 90
Epithelial Ovarian Cancer - Pipeline by Shenzen SiBiono GeneTech Co., Ltd, H2 2015 91
Epithelial Ovarian Cancer - Pipeline by Sotio a.s., H2 2015 92
Epithelial Ovarian Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2015 93
Epithelial Ovarian Cancer - Pipeline by Tesaro, Inc., H2 2015 94
Epithelial Ovarian Cancer - Pipeline by TetraLogic Pharmaceuticals, H2 2015 95
Epithelial Ovarian Cancer - Pipeline by Tyrogenex, Inc., H2 2015 96
Epithelial Ovarian Cancer - Pipeline by VentiRx Pharmaceuticals, Inc., H2 2015 97
Assessment by Monotherapy Products, H2 2015 98
Number of Products by Stage and Target, H2 2015 100
Number of Products by Stage and Mechanism of Action, H2 2015 105
Number of Products by Stage and Route of Administration, H2 2015 110
Number of Products by Stage and Molecule Type, H2 2015 112
Epithelial Ovarian Cancer Therapeutics - Recent Pipeline Updates, H2 2015 296
Epithelial Ovarian Cancer - Dormant Projects, H2 2015 440
Epithelial Ovarian Cancer - Dormant Projects (Contd..1), H2 2015 441
Epithelial Ovarian Cancer - Dormant Projects (Contd..2), H2 2015 442
Epithelial Ovarian Cancer - Discontinued Products, H2 2015 443

List of Figures
Number of Products under Development for Epithelial Ovarian Cancer, H2 2015 18
Number of Products under Development for Epithelial Ovarian Cancer - Comparative Analysis, H2 2015 19
Number of Products under Development by Companies, H2 2015 20
Number of Products under Investigation by Universities/Institutes, H2 2015 26
Comparative Analysis by Clinical Stage Development, H2 2015 28
Comparative Analysis by Early Stage Products, H2 2015 29
Assessment by Monotherapy Products, H2 2015 98
Number of Products by Top 10 Targets, H2 2015 99
Number of Products by Stage and Top 10 Targets, H2 2015 99
Number of Products by Top 10 Mechanism of Actions, H2 2015 104
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 104
Number of Products by Top 10 Routes of Administration, H2 2015 109
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 109
Number of Products by Top 10 Molecule Types, H2 2015 111
Number of Products by Stage and Top 10 Molecule Types, H2 2015 111

List of Table

NA

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *